Analyst Price Targets — NAMS
Latest News for NAMS
NAARDEN, The Netherlands and MIAMI, Sept. 02, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V.
NAARDEN, The Netherlands and MIAMI, Aug. 26, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or…
Handelsbanken Fonder AB lessened its holdings in NewAmsterdam Pharma Company N.V. (NASDAQ: NAMS) by 70.8% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 122,400 shares of the company's stock after selling 296,500 shares during the quarter. Handelsbanken Fonder AB owned 0.10%
NewAmsterdam Pharma Company N.V. (NAMS) Analyst/Investor Day Transcript
NewAmsterdam Pharma NASDAQ: NAMS used its annual Investor Day to outline its cardiovascular outcomes strategy for obicetrapib, provide updates on additional clinical programs and discuss commercial preparations ahead of a potential European launch.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for NAMS.
U.S. House Trading
No House trades found for NAMS.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.